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he Glycoprotein IIb/IIIa
nhibitor Wars
n Update*
eter B. Berger, MD
anville, Pennsylvania
he use of glycoprotein (GP) IIb/IIIa inhibitors during
ercutaneous coronary intervention (PCI) has declined in
ecent years, but 1 of the 3 approved GP IIb/IIIa inhibitors
as still used in about 39% of PCI procedures performed
uring 2008 in the U.S. (Merchant G, personal communi-
ation, June 2010). And, GP IIb/IIIa inhibitors remain “big
usiness”: GP IIb/IIIa inhibitor sales were more than $475
illion in the U.S. alone in 2008 and much more worldwide
Merchant G, personal communication, June 2010).
See pages 463 and 470
Early studies evaluating GP IIb/IIIa inhibitors were
mong the first to document how frequently small, generally
ubclinical procedural myocardial infarctions (MIs) occurred
uring apparently uncomplicated PCI procedures. Empow-
red by such data, advocates for the widespread use of the
rugs successfully changed the lexicon and, in fact, the very
efinition of procedural MI (1). Whereas the definition of
rocedural MI had previously required an elevation of total
reatine kinase (CK) level, most commonly to twice the
pper limit of normal, accompanied by chest pain, electro-
ardiographic changes, or both, the availability of GP
Ib/IIIa inhibitors (which reduce such infarctions by 30% to
0%) empowered advocates for the use of these drugs to
hange the definition from the previously higher threshold
f MI (which occurs in fewer than 1% of patients under-
oing PCI) to a 3-fold increase of not CK but CK-MB,
hich occurs in 4% to 10% of patients undergoing PCI (2).
uch infarctions are rarely accompanied by elevations of
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ankyo (all for more than $10,000).otal CK above normal at all, let alone the development of
eft ventricular wall motion abnormalities. (They can be
een as “microinfarctions,” however, on magnetic resonance
maging [3]).
While it is not possible to imagine how such small
nfarctions can be good for a patient, just how bad they are
as been the subject of much debate. Further complicating
he picture is that several placebo-controlled studies of GP
Ib/IIIa inhibitors, and pooled analyses of such trials, have
evealed a small (0.4%) but statistically significant absolute
eduction in mortality with their use (2). The facts that most
eaths in these trials occurred months after a 24-h
nfusion; that most deaths in the placebo arms occurred in
atients who had not had procedural MIs; and that no
redible mechanism by which these drugs would reduce
eath months after their use has been widely accepted, let
lone confirmed, fanned the flames of controversy (4).
ecently, much attention has been focused on the increased
isk for bleeding with these drugs, particularly by supporters
f bivalirudin, an alternative strategy for preventing proce-
ural complications associated with fewer bleeding compli-
ations than GP IIb/IIIa inhibitors.
Public opinion has gradually turned on the importance
f small procedural infarctions. The recently approved
hird-generation thienopyridine prasugrel is better able to
educe procedural infarctions than clopidogrel, the second-
eneration thienopyridine that is the second-best selling
rug in the world, with sales of more than $8 billion per year
5,6). However, the decision to approve prasugrel has been
idely criticized because of questions about the significance
f such procedural infarctions and because prasugrel, like
P IIb/IIIa inhibitors, increases the frequency of bleeding
omplications that can occasionally be fatal (6). Nonethe-
ess, the ability to reduce procedural MI so effectively during
CI suggests that GP IIb/IIIa inhibitors will continue to
lay a role in the future.
There exist 3 different GP IIb/IIIa inhibitors approved
or use: abciximab (Eli Lilly & Company, Indianapolis,
ndiana), eptifibatide (Schering-Plough, Kenilworth, New
ersey), and tirofiban (Medicure, Winnipeg, Canada). The
erce competition among the companies that make and
arket these drugs, fighting for their share of the billion-
ollar market, has kept the issue of the comparative effec-
iveness of the GP IIb/IIIa inhibitors in the spotlight. The
normous differences in the price among the 3 agents make the
omparative effectiveness and relative costs of these drugs
mportant in this era of health care reform. The average
holesale price of abciximab is $1,836.90 (for a 12-h
nfusion) and of eptifibatide is $1,121.81 and tirofiban is
711.72 (for 18-h infusions) for an 80-kg patient with
ormal renal function (Merchant G, personal communica-
ion, June 2010). Many argue about whether price ought to
e a strong consideration when 2 competing therapies differ
n efficacy and safety. If, however, 2 treatments are similar in
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ost important, consideration.
Some believe that the primary determinant of the effec-
iveness of these drugs is their ability to maintain a high
evel of GP IIb/IIIa receptor occupancy after the initial
olus and throughout the infusion. Interestingly, these
rugs were developed so rapidly, with so little phase 1 and
study, that the “wrong,” or suboptimal, doses for all 3
gents were rushed into clinical practice. Abciximab, first to
arket, achieves very high levels of receptor occupancy after
ts bolus, but levels decline during the infusion (7). Declin-
ng levels of receptor occupancy during the infusion, allowing
p-regulation of unblocked receptors, are believed by some to
e a reason that the large, placebo-controlled GUSTO IV
Global Use of Strategies to Open Occluded Coronary Arter-
es) trial of abciximab, studying prolonged infusions of the
rug, was not only negative but also associated with increas-
ng rates of thrombotic complications with increasing du-
ations of infusion (8). For PCI, eptifibatide was initially
tudied using a single bolus dose, 135 g/kg, followed by a
.5 or 0.75 g/kg/min infusion, that was also found to be
oo low (7); the dosing was subsequently greatly increased to
double bolus dose of 180 g, 10 min apart, followed by a
.0 g/kg/min infusion (7). This dose of eptifibatide ap-
ears to be the “right” one, leading to high levels of receptor
ccupancy throughout an 18-h infusion (7). Tirofiban, the
nly drug whose then owner Merck & Company (White-
ouse Station, New Jersey) was bold enough to perform a
ead-to-head trial comparing its drug with another, was also
ound to have too low of an initial bolus (7). Further studies led
o an increase in the initial bolus dose of 150%, from 10 to
5g/kg (7). With this bolus dose, receptor occupancy is high,
nd it remains so throughout an 18-h infusion period (7).
Other potentially important differences exist between the
rugs than receptor occupancy, however. Abciximab is a
arge molecule that binds the GP IIb/IIIa receptor with very
igh affinity (though not irreversibly, as has often been
eported) and, unlike the small-molecule agents, also avidly
inds the vitronectin (v3) receptor (7). Very little un-
ound abciximab remains circulating in the bloodstream (7).
transfusion of platelets into a patient on abciximab leads
o release of abciximab from native platelet GP IIb/IIIa
eceptors and transfer to transfused platelets (7). When this
ccurs, overall receptor occupancy of the entire platelet pool
s so low that normal platelet aggregability is restored (7). In
ontrast, eptifibatide and tirofiban are small molecules, and
heir administration results in as many as 200 molecules of
irculating drug for every molecule that binds to a receptor
7). Therefore, transfused platelets become bound to the
irculating unbound GP IIb/IIIa molecules, and platelet
ransfusions are less able to restore normal platelet function
9). Thus, many believe that eptifibatide and tirofiban are
ore alike than either is to abciximab. However, tirofiban
inds platelet GP IIb/IIIa receptors with great affinity,
uch like abciximab, in contrast to eptifibatide, whose
olecules are frequently releasing and rebinding platelet GP pIb/IIIa receptors, allowing (at least theoretically) fibrinogen
olecules to bind GP IIb/IIIa receptors and cross-link with
ther platelets, the mechanism by which platelet clots form
7). The truth is that while such hypotheses are intellectually
timulating and the fuel for great debates, what really
atters is how the drugs perform clinically.
The only large clinical trial comparing 2 agents appro-
riately sized to detect a difference in a combined end point
f death and MI, the TARGET (Do Tirofiban and ReoPro
ive Similar Efficacy Trial), revealed that abciximab is
uperior to tirofiban when the original low, 10-g bolus
ose of tirofiban is used (10). However, because the doses of
ptifibatide and tirofiban have been increased, several
maller trials comparing different GP IIb/IIIa inhibitors,
ncluding abciximab versus tirofiban and abciximab versus
ptifibatide, have been performed, including the EVA-AMI
Eptifibatide Versus Abciximab in Primary PCI for Acute
yocardial Infarction) trial, published in this issue of the
ournal (11–14). In this small trial in which 427 patients
ere enrolled, the primary end point was a surrogate end
oint, ST-segment resolution. The trial used a noninferi-
rity design with a noninferiority margin of 15%. The
nvestigators concluded that in primary PCI, eptifibatide
eems equally effective and safe as abciximab with respect to
yocardial reperfusion and clinical events. In reality, the
rial was enormously undersized to assess a difference in
linical events (and in fact, there was a sizable difference in
ortality and reinfarction between the agents, in opposite
irections). This study differs from most in that the eptifi-
atide infusion continued for 24 h; most have administered
t for 16 to 18 h. The impact of this is unknown. Although
lacebo-controlled trials of eptifibatide in ST-segment ele-
ation MI have been performed, this was the first compar-
ng eptifibatide and abciximab specifically in patients with
T-segment elevation MI. In this issue of the Journal, a
alented group of investigators from Sweden analyze their
ationwide registry and similarly conclude that the 2 agents,
bciximab and eptifibatide, have similar efficacy (15). Well
ritten, and using elegant statistical methodology, the study
as carefully done. But many potentially important variables
ere not known and could not be included in the analysis.
nd, one should remember the limitations of registries in
valuating the efficacy of drugs. This same registry identified
n absolute reduction in mortality of 5.3%, and an adjusted
elative reduction in death of 25%, with statins in just the 1
ear after a MI, which is not a credible finding (16). Such
egistry analyses can perhaps provide insight into direction-
lity and proportionality and should be used to generate
ypotheses, but they ought not be considered able to
rovide accurate estimates of real differences between treat-
ents. Interestingly, however, the recent updated ST-
egment elevation MI and PCI guidelines judged the
otality of evidence to indicate that the 3 GP IIb/IIIa
ntagonists have similar effectiveness in the setting of
rimary PCI (17). Although this may be true, we cannot be
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The GP IIb/IIIa Inhibitor Wars August 3, 2010:476–8ertain, and the data ought not be considered convincing or
s level 1 evidence.
Based on the 30-day outcomes of patients undergoing
rimary PCI in recent trials, a trial comparing 2 GP IIb/IIIa
gents would need to enroll more than 10,000 patients to
how noninferiority of 2 agents if any small but clinically
ignificant margin of noninferiority were used. Such a trial
ould be so expensive that it is very unlikely one will ever be
erformed.
What, then, are physicians to do, given the uncertainty
bout how the 3 GP IIb/IIIa inhibitor drugs compare with
ne another? No definitive answer can be provided. Some
hysicians will continue to choose the most studied agents,
ejecting undersized trials as inconclusive (which they are).
thers are comfortable choosing a promising but less
tudied agent. Still others will choose the cheapest agent.
till others (unfortunately) choose the agent whose sales-
eople are most effective, friendly, or attractive (18).
In this era of constrained health care dollars, physicians
ught to have all of the evidence they need to make the most
nformed decisions for their patients. The investigators of
oth studies are to be congratulated for contributing to the
xisting body of evidence.
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bberger@geisinger.edu.
EFERENCES
1. Holmes DR, Berger PB. Editorial: troponisms, necrossettes, enzyme
leaks, CPK bumps, and infarctlets. What’s behind this new lexicon and
what does it add? Circulation 2001;104:627–9.
2. Kong D, Hasselblad V, Harrington R, et al. Meta-analysis of survival
with platelet glycoprotein IIb/IIIa antagonists for percutaneous coro-
nary interventions. Am J Cardiol 2003;92:651–5.
3. Ricciardi MJ, Wu E, Davidson CJ, et al. Visualization of discrete
microinfarction after percutaneous coronary intervention associated
with mild creatine kinase-MB elevation. Circulation 2001;103:
2780–3.
4. Anderson KA, Califf RM, Stone GW, et al. Long-term mortality
benefit with abciximab in patients undergoing percutaneous coronary
intervention. J Am Coll Cardiol 2001;37:2059–65.
5. Curtiss FR, Fairman KA. Pharmacy benefit spending poised to
increase for antithrombotic drug therapy-prasugrel versus clopidogrel.
J Manag Care Pharm 2009;15:414–6. m6. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus
clopidogrel in patients with acute coronary syndromes. N Engl J Med
2007;357:2001–15.
7. Schneider DJ, Aggarwal A. Development of glycoprotein IIb-IIIa
antagonists: translation from pharmacodynamic effect to clinical ben-
efit. Expert Rev Cardiovasc Ther 2004;2:903–13.
8. The GUSTO-IV ACS Investigators. Effect of glycoprotein IIb/IIIa
receptor blocker abciximab on outcome in patients with acute coronary
syndromes without early coronary revascularization: the GUSTO
IV-ACS randomized trial. Lancet 2001;357:1915–24.
9. Li YF, Spencer F, Becker R. Comparative efficacy of fibrinogen and
platelet supplementation on the in vitro reversibility of competitive
glycoprotein IIb/IIIa (IIb/3) receptor-directed platelet inhibition.
Am Heart J 2001;142:204–10.
0. Topol EJ, Moliterno DJ, Herrmann HC et al. Comparison of two
platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for
the prevention of ischemic events with percutaneous coronary revas-
cularization. N Engl J Med 2001;344:1888–94.
1. Valgimigli M, Biondi-Zoccai G, Tebaldi M et al. Tirofiban as
adjunctive therapy for acute coronary syndromes and percutaneous
coronary intervention: a meta-analysis of randomized trials. Eur
Heart J 2010;31:35–49.
2. Gurm H, Tamhane U, Meier P, et al. A comparison of abciximab and
small molecule glycoprotein IIb/IIIa inhibitors in patients undergoing
primary percutaneous coronary intervention: a meta-analysis of con-
temporary randomized controlled trials. Circ Cardiovasc Intervent
2009;2:230–6.
3. De Luca G, Ucci G, Cassetti E, et al. Benefits from small molecule
administration as compared with abciximab among patients with
ST-segment elevation myocardial infarction treated with primary
angioplasty: a meta-analysis. J Am Coll Cardiol 2009;53:1668–73.
4. Zeymer U, Margenet A, Haude M, et al. Randomized comparison of
eptifibatide versus abciximab in primary percutaneous coronary inter-
vention in patients with acute ST-segment elevation myocardial
infarction: results of the EVA-AMI trial. J Am Coll Cardiol 2010;56:
463–9.
5. Åkerblom A, James SK, Koutouzis M, et al. Eptifibatide is non-
inferior to abciximab in primary percutaneous coronary intervention:
results from the SCAAR (Swedish Coronary Angiography and An-
gioplasty Registry). J Am Coll Cardiol 2010;56:470–5.
6. Stenestrand U, Wallentin L, for the Swedish Register of Cardiac
Intensive Care (RIKS-HIA). Early statin treatment following acute
myocardial infarction and 1-year survival. JAMA 2001;285:430–6.
7. Kushner FG, Hand M, Smith SC Jr., et al. 2009 focused updates:
ACC/AHA guidelines for the management of patients with ST-
elevation myocardial infarction (updating the 2004 guideline and 2007
focused update) and ACC/AHA/SCAI guidelines on percutaneous
coronary intervention (updating the 2005 guideline and 2007 focused
update): a report of the American College of Cardiology Foundation/
American Heart Association Task Force on Practice Guidelines. J Am
Coll Cardiol 2009;54:2205–41.
8. Saul S. Gimme an Rx! Cheerleaders pep up drug sales. The New York
Times. November 28, 2005.
ey Words: glycoprotein IIb/IIIa inhibitors y ST-segment elevation
yocardial infarction y primary percutaneous coronary intervention.
